Framingham and Czech partnership seeks new Alzheimer’s test
Image | Courtesy of Google Maps
Alzheon headquarters in Framingham
The Framingham pharmaceutical firm Alzheon has partnered with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences to develop a diagnostic assay to measure substances believed to be neurotoxic drivers of Alzheimer’s disease pathology.
Alzheon is a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease. The new partnership will build upon work the company has done with Alzheimer’s in the past to develop a clinical assay to measure neurotoxic beta amyloid oligomers in human cerebrospinal fluid. Clinical studies and trials have linked these substances to Alzheimer’s disease.
This new assay could help in both research and treatment of disease, by revealing aspects of the disease mechanism and guiding efforts to stop or prevent Alzheimer’s.
“Such a tool is not only valuable as a diagnostic for patients with Alzheimer’s disease, but also offers a way to monitor response of patients to therapy,” said Dr. Martin Tolar, the Alzheon founder, president and CEO.
The IOCB will be primarily responsible for the development and validation of the assay to detect amyloid oligomers and to measure the change in amyloid levels following treatment with Alzheon’s anti-oligomer agents, such as ALZ-801.
WBJ Web Partners
Most Recent
Most Recent
0 Comments